Oslo, 21 December 2018 – Navamedic ASA (OSE: NAVA) announces that the Board of Directors has entered into a process for a potential acquisition of Novicus Pharma AS.
Reference is made to the summon for the extraordinary general assembly 20 December 2018, outlining a proposal from Ingerø Reiten Investment Company to "evaluate and execute an acquisition of Novicus Pharma AS, a pharmaceutical company focusing on non-prescription and consumer health products for the Norwegian and Nordic market".
The Board of Directors has today entered into a process for a potential acquisition of Novicus Pharma AS.
For further information, please contact:
Toril Ås, CFO, Navamedic
Telephone: +47 957 01 071
About Novicus Pharma AS
Novicus Pharma is a pharmaceutical company focusing on OTC (non-prescription) and consumer health products for the Norwegian and Nordic market. The company was founded by the former management of Weifa ASA, and the founders have executive professional experience from the pharma-, OTC- and FMCG industries.
Navamedic ASA is a Norwegian medtech and pharmaceutical products company, delivering products to patients, hospitals and pharmacies in the Nordic and selected European markets. The Group has recently established a Medtech business unit which is currently introducing the next generation digital urine meter for use in intensive care, Sippi ®. Navamedic's Pharma and Healthcare business is a distributor of products supplied by a number of pharmaceutical and medical device manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA). www.navamedic.com
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.